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Abstract
Background: Epidemiological studies have clearly validated the association between hepatitis B virus (HBV)
infection and hepatocellular carcinoma (HCC). Patients with chronic HBV infection are at increased risk of HCC, in
particular those with active liver disease and cirrhosis.
Methods: We catalogued all published interactions between HBV and human proteins, identifying 250 descriptions
of HBV and human protein interactions and 146 unique human proteins that interact with HBV proteins by text
mining.
Results: Integration of this data set into a reconstructed human interactome showed that cellular proteins
interacting with HBV are made up of core proteins that are interconnected with many pathways. A global analysis
based on functional annotation highlighted the enrichment of cellular pathways targeted by HBV.
Conclusions: By connecting the cellular proteins targeted by HBV, we have constructed a central network of
proteins associated with hepatocellular carcinoma, which might be to regard as the basis of a detailed map for
tracking new cellular interactions, and guiding future investigations.
Background
Hepatitis B virus is one of the most common infectious
diseases in the world, and 43 years after its discovery, it
still has a great impact on health, particularly in devel-
oping countries. More than 350 million people world-
wide are known to be chronic carriers of HBV, and each
year 15 million people die of hepatitis [1].
T h eH B Vv i r a lg e n o m ei sar e l a xed-circular, partially
duplex DNA of 3,200 base pairs. It has five genes encod-
ing polymerase, pre-S1/pre-S2/S, X protein, precore/
core protein, and the ID2828293 gene which is not well
understood without an official gene symbol or descrip-
tion[2]. These proteins can also trans-activate other
cellular genes, which may play a role in hepatocarcino-
genesis [3].
Hepatocellular carcinoma is one of the most common
fatal cancers worldwide [4]. HBV is strongly associated
with HCC by its presence in the tumor cell and by the
striking role of persistent HBV infection as a risk factor
for the development of HCC[2]. The incidence of HCC
in many countries is increasing in parallel to an increase
in chronic HBV infection[1]. It is generally shown that
vaccination significantly decreases the incidence of
HCC. Moreover, preventing the most severe HBV dis-
ease consequences in infected people, such as cirrhosis
and fibrosis, will require appropriate therapeutic agents
and reduces the risk of developing HCC [5].
To make progress in understanding the mechanisms
of viral pathogenesis and the relationship of HCC with
HBV, it is important to sort out the interactions of HBV
proteins with the vast array of human cellular proteins.
While these interactions can be direct viral and host cell
protein-protein interactions, many are indirect, includ-
ing regulatory interactions that alter human gene
expression[2]. Rapidly growing knowledge about the
protein-protein interaction (PPI) networks (interactome)
for hosts and pathogens is beginning to be used to
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approach to a virus-human protein interactome network
revealed that host interactors tend to be enriched in
proteins that are highly connected in the cellular net-
work [7]. These “hub proteins” are thought to be essen-
tial for normal cell functioning and during pathogenesis.
Therefore, clarification of the genetic picture of hepato-
carcinogenesis caused by HBV infection might provide
clues toward achieving a decrease in the incidence of
HCC and establishing effective treatments[8].
In this study, we attempted to catalogue all published
interactions between HBV and human proteins, particularly
human proteins associated with hepatocellular carcinomas,
for an in-depth review and understanding of these interac-
tions. Our aim was to enhance insight into HBV replication
and pathogenesis on a cellular level, in order to assist in
accelerating the development of effective therapeutics.
Methods
Text mining of human proteins that interact with HBV
and are associated with HCC
To facilitate the development of a database describing
HBV and human protein interactions, a detailed litera-
ture search was carried out on the PubMed database to
analyze binary interactions between HBV and human
proteins. We used the automatic text mining pipeline
method of NLP (Natural Language Processing), followed
by an expert curation process, independent of the
results obtained at this step. The data compilation pro-
cess included publications until January 2009.
In brief, we first searched the document using relevant
keywords and transformed it into XML format. We then
used the Lingpipe Kit sentence tokenization tool (sen-
tence partition) to separate the abstract text into a single
sentence. Follow-up analysis used the sentence as a
basic unit. The human genes mentioned in the sen-
tences were extracted using ABNER software [9], and
the gene name was normalized based on the Entrez
database in order to facilitate analysis and comparison.
For example, an extracted conjunction gene description
such as “STAT3/5 gene” would be resolved into STAT3
gene and STAT5 gene. We built a protein-protein inter-
action verb dictionary [10],i n c l u d i n gt e r m ss u c ha s
repress, regulate, inhibit, interact, phosphorylate, down-
regulate and up-regulate. All of the verbs and their var-
iants were derived from the BioNLP project http://
bionlp.sourceforge.net/. Using the Lingpipe Toolkit, we
then detected protein interaction verbs in sentences and
gathered the HBV protein and synonym names (com-
piled from the Entrez database). Statistical analysis of
sentences in which a human protein, an interaction verb
and an HBV protein were all present at the same time
(co-occurrence) was used to determine HBV protein
and HHBV interaction relationships.
Using the same NLP methods, we extracted literature
related to hepatocellular carcinoma from PubMed and
identified the interactions and relationships between
HBV proteins and HHCC.
The integrated human interactome network (H-H
network)
In order to make the HBV protein and human protein
HHBV interaction network more complete, we inte-
grated the HHBV and HHBV interaction relationships.
The HHBV and HHBV protein interaction data were gath-
ered from the STRING database http://string.embl.de/,
which includes experimental evidence of protein inter-
actions (e.g., yeast two-hybrid), protein interaction data-
bases (e.g., the KEGG pathway) and text mining
co-occurrence. The algorithm for human protein to
human protein interaction relationships was previously
described [11]. NCBI official gene names were used to
combine protein ACC, protein ID, gene name, symbol
or alias from different genome reference databases (e.g.,
ENSEMBL, UNIPROT, NCBI, INTACT, HPRD, etc.)
and to eliminate interaction redundancy due to the exis-
t e n c eo fd i f f e r e n tp r o t e i ni s o f o r m sf o ras i n g l eg e n e .
Thus, the gene name was used in the text to identify the
protein. Finally, we only used non-redundant protein-
protein interactions to build the human interactome
data set.
The network structure of the HBV protein to human
protein interaction relationships and the human protein
to human protein interaction relationships was mapped
using Medusa software.
Gene ontology analysis
To demonstrate the complexity of the HBV-human
protein interaction network, the catalogued data were
analyzed using gene ontology [12]. Gene ontology is a
set of three structured controlled ontologies that
describe gene products in terms of their associated cel-
lular component (CC), biological process (BP), or
molecular function (MF) in a species-independent
manner. We performed gene ontology analysis using
EASE software. Enrichment p-values were adjusted
by the Benjamini and Hochberg multiple test correc-
tion [13].
Functional analysis using KEGG annotations
C e l l u l a rp a t h w a yd a t aw e r er e t r i e v e df r o mK E G G ,t h e
Kyoto Encyclopedia of Genes and Genomes http://www.
genome.jp/kegg/, and were used to annotate NCBI gene
functions [14]. For each viral-host protein interaction,
the enrichment of a specific KEGG pathway was tested
using a Fisher’s exact test followed by the Benjamini
and Hochberg multiple test correction to control for the
false discovery rate [15].
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HBV protein to human protein interaction relationships
and human protein to human protein interaction rela-
tionships were mapped and visualized in a network
structure using Medusa software [16].
Results
Construction of an HBV-human interactome network
In order to analyze the interactions between HBV and
human proteins, literature indexed in PubMed was
searched using keywords [e.g., ("HBV” [title] OR “hepati-
tis B” [title] AND ("1980/01/01” [PDAT]: “2009/01/01”
[PDAT]))]. From the entire database, 52,531 published
journal abstracts were identified by NLP (Natural Lan-
guage Processing) queries. Further text analysis revealed
a total of 146 HBV-targeted human protein (HHBV)
from 250 summary descriptions that reported putative
interactions between HBV and human proteins, com-
prising 150 unique HBV to human protein interactions.
Figure 1A summarizes the HBV protein interactions cat-
alogued from these papers (see Additional file 1, Table
S1 for a listing of all interactions).
Based on the text in the original journal articles
selected by keywords and combining similar keywords,
we identified the most important functional keyword
used by the authors to describe the interaction. Twenty-
five unique keywords were associated with these
descriptions. The most frequently used keywords in the
database were “interact,” 25.77%; “activate,” 13.08%;
“inhibit,” 8.46%; “associate,” 9.23%; “regulate,” 8.46%,
including “upregulate,” 3.36%, and “downregulate,”
1.54%; and “phosphorylate,” 7.31% (Figure 1B, and see
Additional file 1, Table S2 for a listing of all keywords).
While it could not be excluded that some of these
interactions are nonspecific or human errors, the catalo-
gued interactions provide a unique collection of data
collectively generated from the available scientific
literature.
Analysis of the HBV-infection network showed that X
protein and core protein were the most connected pro-
teins (Figure 1A), with 122 (83.5%) and 15 (10.3%) of
the total HHBV identified in the database, including
many transcription factors and regulators. This high-
lights the potential multi-functionality of these proteins
during infection (Figure 1B, Additional file 1, Table S1).
Highly interacting proteins are known to be significantly
more disordered than low-degree (LD) proteins [17].
Interestingly, X protein and core protein are predicted
to contain one intrinsic disordered region (data not
shown) according to DISOPRED2 [18]. In addition, five
HHBV such as MAPK8, E2F1, and NF-kappa 1were tar-
geted by more than one HBV protein, suggesting these
proteins might play important roles in HBV replication
and pathogenesis (Additional file 1, Table S3).
A human PPI network has been reconstructed from
eight databases [19]. This network is composed of
44,223 non-redundant PPIs among 9,520 different pro-
teins, corresponding to 30% of the human proteome
(the remaining proteins have no known cellular partners
and, therefore, cannot be included in this network).
Interestingly, HHBV are clearly over-represented in this
H-H network (134 (92%) of the total HHBV). Analysis of
the HHBV-HHBV sub-network (all connected 146 HHBV
proteins), which is composed of 1,977 non-redundant
PPIs among different HHBV and more interconnected
than the H-H network, indicated that HBV proteins
have a strong tendency to interact with highly con-
nected cellular proteins (Figure 1B, Additional file 1,
Table S4). This also suggests that HBV preferentially
targets host proteins already known to be engaged in
protein-protein interactions.
Analysis of the relationship between hepatocellular
carcinoma and HHBV
In order to provide a global view of human proteins
involved in HCC associated with the HBV - with the
aim of clarifying the relationship between HBV proteins
and hepatocellular carcinoma-associated proteins
(HHCC) - we also made use of NLP methods to extract
literature related to HCC from PubMed.
Using the keyword search [e.g., (liver cancer “[title]
OR” hepatocellular carcinoma “[title] OR” Liver Neo-
plasm “[title] OR” Liver Neoplasms “[title] AND (”
1980/01/01 “[PDAT] :” 2009/01/01 “[PDAT]))], we
retrieved 19,050 related articles. Based on a combination
of text mining procedures and expert curation, a total of
666 HHCC (number of PMID greater than or equal to 2)
were identified from 6,709 summary descriptions (Addi-
tional file 1, Table S5). Among these, nine of HHCC had
more than 100 PMID references (Figure 2A).
Compared with HHBV,7 6p r o t e i n s( H HBV-HHCC)
among the HHBV (146) were also hepatocellular carci-
noma-associated proteins (Figure 2B, Additional file 1,
Table S6). Four HHBV-HHCC’s had more than 100 PMID
references (Figure 2A).
Gene ontology and KEGG pathway analysis
The 146 HHBV could be classified into 18 mutually
dependent functional sets, resulting in 17 cellular pro-
cesses in 12 cellular components according to the gene
ontology analysis. Accordingly, the 76 HHBV-HHCC could
be classified into 14 functional sets, resulting in 16 cel-
lular processes in eight cellular components (Additional
file 1, Table S7).
A ss h o w ni nF i g u r e2 C ,m o s to ft h ef u n c t i o n a lp r o f i l -
ing showed transcriptional activity, DNA binding,
kinase activity, signal transducer activity, cytokine
activity and growth factor activity. These functions are
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Page 3 of 10Figure 1 HBV and human protein interaction network. (A) Summary of the HBV-human protein (HHBV) interactions. (B) HBV and HHBV
interaction network. Red square: HBV protein. Circular node: HHBV. For HBV-HHBV interactions, green lines correspond to activate; blue lines, to
inhibit; and red lines, to interact (activate or inhibit unknown), all interaction keywords can be found in Additional file 1, Table S2. For HHBV-HHBV
interactions, purple indicates evidence from experiments (High-throughput yeast two-hybrid experiment data was collected from public data
sources); light blue, from database (Protein - protein interaction relationship was extracted from KEGG pathway database); and grass green, from
literature text mining (Scattered literatures about low throughput research on protein - protein interaction were parsed with an in-house
computer program), which derived from the Additional file 1, Table S4.
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cell differentiation, signal transduction, cell communi-
cation, apoptosis, regulation of gene expression, cell
proliferation and cell development. These biological
processes are thought to play important roles in the
pathogenesis of HCC [2].
To better understand the biological functions of
HHBV-HHCC, we determined the enrichment of specific
pathways for all interactors. Of the 76 proteins (HHBV-
HHCC), 63 (~83%) could be mapped to 9 pathways (P
< 0.01) of 202 KEGG human pathway database (Addi-
tional file 1, Table S8). 6 pathways, namely apoptosis,
Figure 2 Analysis of the relationship between HHCC and HHBV. (A) Gene list of top nine HHCC. (B) Overlap between HHCC and HHBV. The blue
area corresponds to HHBV; the yellow area, to HHCC: and the green area, to HHBV-HHCC. (C) Gene Ontology analysis of HHBV and HHBV-HHCC.
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naling pathway, MAPK signaling pathway and ErbB
signaling pathway were significantly enriched (P <
0.0001).
Functional analysis of the HBV-human interaction
network
Dysregulation of the balance of survival or apoptosis
represents a protumorigenic principle in human hepato-
carcinogenesis [20]. To provide a review of the current
findings about how the balance is dysregulated by HBV
in HCC, we integrated 57 HHBV-HHCC into one molecu-
lar interaction network. As shown in Figure 3, these
HHBV-HHCC can constitute several signal pathways, such
a sJ A K / S T A T ,M E K / E R K ,P I 3 K / A K T ,N F B, MAPK,
SAPK/JNK, and p53 signal pathways, and mediate many
opposing cellular functions, including function in cell
cycle and apoptosis regulation [21].
The expression of cytokines like IL2, IL6, TNF and
receptors like insulin-like growth factor 1 receptor
(IGF1R) are up-regulated, which can activate kinases
like the Src tyrosine kinases and the downstream path-
way such as MAPK, MEK/ERK. HBx activates the com-
ponents of the JAK/STAT, MEK/ERK, PI3K/AKT,
MAPK, SAPK/JNK signalling pathways, leading to acti-
vation of a variety of transcription factors such as
STAT-3, ELK-1, NF-B, CREB, b-catenin, c-Fos, c-Jun,
c-Myc, etc. Meanwhile, some physiological proapoptotic
molecules are down-regulated or inactivated, such as
Fas, p53, DR5 or FADD. HBx can bind to the C-termi-
nus of p53 sequesters in the cytoplasm and prevent it
from entering the nucleus [2], failure to up-regulate
genes, such as IGFBP3, p21WAF1, Bax or Fas, thereby
inactivating several critical p53 dependent activities,
including p53 mediated apoptosis. Moreover, the down-
regulation of PTEN and the activation of PI3K/AKT-
Figure 3 Functional analysis of the HBV-human interaction network. In black, HHBV-HHCC either down-regulated or inactivated; in red, HHBV-
HHCC either up-regulated or overactivated; with underline, HHBV-HHCC interact (activate or inhibit unknown); in box, non-HHBV-HHCC molecules in
pathways. See text for details.
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tosis and down-regulation of caspase 3 activity. How-
ever, HBx also promotes the apoptosis by regulating the
expressions of Fas/FasL, Bax/Bcl-2, and c-Myc gene.
Cell cycle is regulated by activity of cyclins, cyclin
dependent kinases (CDKs), and cyclin dependent kinase
inhibitors (CDKIs), which generally function within sev-
eral pathways [22]. HBx can repress the transcription of
p21WAF1 and p16INK4A, leading to increase the rate and
level of activation of the CDK2 and CDK4. HBx also
inhibit the pRb tumor suppressor and increase E2F1
activity, and regulate the expression of MDM2, cyclin
D1 and cyclin B1. Ultimately, HBx has been shown to
stimulate cell cycle progression by accelerating transit
through the G1/S and G2/M checkpoints [2].
In brief, regardless of the mechanism, the aberrant
gene expression and deregulated of these pathways ulti-
mately leads to generate a unique response, the accel-
eration of cell cycle progression and cell growth,
increased differentiation and proliferation, repression
of apoptosis, and contribute to cell survival and
oncogenesis.
Discussion
Developing an HBV-human interactome network by
mapping the interactions of viral proteins with host pro-
teins may give us a comprehensive view of viral infec-
tion at the protein level, and provide clues to
understanding the development of end-stage complica-
tions such as cirrhosis and HCC. In this study, we used
an NLP method to analyze the PubMed literature data-
base for articles regarding HBV and human protein
interactions. With an exhaustive analysis of the litera-
ture and databases, we identified 146 HHBV that are cru-
cial for hepatitis B virus infections. These HHBV are
involved in numerous functions associated with onco-
genesis, and through screening and mapping the HHCC,
we found that about half of the HHBV were also hepato-
cellular carcinoma-associated proteins such as IL6,
STAT3[23], MMP9, TGFB1 [24] and TP53 [25]. This
may explain why hepatitis B virus is the primary risk
factor for the development of HCC. The Gene ontology
analysis show that most of the functional profiling (such
as transcriptional activity, DNA binding, kinase activity
and signal transducer activity) and biological processes
(such as cell differentiation, apoptosis, cell proliferation
and cell development) are thought to play important
roles in the pathogenesis of HCC.
KEGG functional annotation was used to analyze the
biological functions of HHBV-HHCC.8 3 %o fH HBV-HHCC
could be mapped to 9 pathways (P < 0.01) (Additional
file 1, Table S8), apoptosis, cell cycle, p53 signaling
pathway, toll-like receptor signaling pathway, MAPK sig-
naling pathway and ErbB signaling pathway were
significantly enriched (P < 0.0001). Although this
approach is biased because functions have not yet been
attributed to all proteins, it remains a powerful way of
incorporating conventional biology into systems-level
data sets[26].
Toll-like receptors (TLRs) are known to play a key
role in the innate immune system, particularly in the
inflammatory response against invading pathogens [27].
In PBMCs of HBV-infected patients, TLR7 expression
and TLR9 mRNA are down-regulated, but TLR9 shows
increased protein expression [28], which may play
important roles in cancer cells[29]. The ErbB receptor
tyrosine kinases play important roles in both normal
physiology and cancer. ErbB2 (HER-2/neu) has been
identified as an important regulator of the metastatic
potential of breast cancer, which is the principal cause
of death [30]. The detailed relationship between HBV
with ErbB receptor and toll-like receptors pathways has
not been investigated. Further studies of the functional
changes in these pathways in response to HBV infection
will provide clear information about the oncogenesis of
hepatocellular carcinoma.
We also identified focal adhesion (p < 0.001) might be
as a novel pathway affected by HBV through the KEGG
pathway analysis (Additional file 1, Table S8). When
focal adhesion is deregulated, it can lead to perturbation
of cell mobility, detachment from the ECM and tumor
initiation and progression [31]. HBx can increase the
migratory phenotype of hepatoma cells through the up-
regulation of matrix metalloproteinases-1 (MMP1) and
MMP9[32]. Moreover, HBx represses several cell adhe-
sion molecules and cytoskeleton proteins, including
E-cadherin, integrin, fibronectin, CD47, and CD44 [2].
Regulation of focal adhesion was also identified as a new
function that is affected by HCV, primarily through the
NS3 and NS5A proteins [26]. However, the impact of
HBV protein on focal adhesion should be further
assessed using a cellular adhesion assay.
Moreover, a large number of HHBV-HHCC could be
significantly enriched in apoptosis, cell cycle, p53 and
MAPK signaling pathway (P < 0.0001), which are very
crucial in the oncogenesis of HCC [20]. Therefore, we
integrated these HHBV-HHCC into one molecular interac-
tion map, which delineate many different oncogenic
pathways involved in hepatocarcinogenesis. These pro-
teins are at the center of many different pathways (such
a sJ A K / S T A T ,M E K / E R K ,P I 3 K / A K T ,N F B, MAPK,
SAPK/JNK, and p53 signal pathways) that regulate many
important biological processes, including cell differentia-
tion, apoptosis, cell proliferation, cell cycle, etc. HBx can
modulate both pre-apoptotic and anti-apoptotic path-
ways, some physiological pro-apoptotic HHBV-HHCC
molecules are down-regulated or inactivated, even more
anti-apoptotic signals HHBV-HHCC molecule are up-
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number of the molecular events are altered, leading to
the disruption of the balance between death and survival
in the preneoplastic hepatocytes and the uncontrolled
growth of tumour cell [20,21].
Accordingly, hepatocellular carcinoma show stronger
requirements of these intracellular pathways to survive,
therefore, therapeutic strategies to selectively inhibit
anti-apoptotic signals in HCC cells might have the
potential to provide effective tools to treat HCC in the
future [4,20]. Interestingly, recently studies show that
the multikinase inhibitor drug sorafenib can induce
HCC apoptosis through inhibiting the RAF/MEK/ERK
pathway [33]. Another receptor tyrosine kinase inhibitor
drug, sunitinib is also a strong apoptosis inducer in dif-
ferent tumor cells, especially in the presence of inhibi-
tors of the PI3K/Akt/mTOR pathway [34]. Similar
situations might be found with other multikinase that
are on the way towards approval for HCC therapy [34].
Therefore, the data of HHBV and the most specific
annotations for each human protein can be used as a
resource for researchers interested in prioritizing drug
targets (Additional file 1, Table S1). For example, the
damage-specific DNA binding protein 1 (DDB1) had 14
identified interactions with HBV X protein (Additional
file 1, Table S1), which is a highly conserved protein
implicated in DNA repair and cell cycle regulation [35].
HBx in association with DDB1 may stimulate HBV
replication and induce genetic instability in hepatocytes,
thereby contributing to HCC development, and making
this HBV-host protein interaction as an attractive target
for new therapeutic interventions [36].
I na d d i t i o n ,i tm u s tb ep o i n to u tt h a tn o ta l lo ft h e
papers that report HBV binding proteins from cell lines
validate the binding of these host proteins to the corre-
sponding HBV antigen by co-immunoprecipitation of
extracts from clinical samples (infected liver and HCC
tissue). At the same time, it raises a number of ques-
tions need further studies such as whether all the identi-
fied interactions really occur and have functional
consequences. To identify new molecules involved
in hepatocarcinogenesis, we can establish of high-
throughput yeast two-hybrid (Y2H) screens and co-
affinity purification methods for large scale analysis of
protein-protein interaction[26], and integrate of chip-
based chromatin-immunoprecipitation (ChIP-chip) with
expression-microarray profiling for the identification of
candidate genes directly regulated by HBV[37].
Finally, a number of HHBV-HHCC and cellular pro-
cesses have been studied, but many of the molecular
events involved in the pathophysiology of HCC are still
unclear. One single identified HHBV-HHCC may be
involved in some new multiple, independently regulated
HCC-specific pathways. Hence, the HBV-human protein
interaction network might be to regard as the basis of a
detailed map for tracking new cellular interactions, and
guiding future investigations of the molecular mechan-
ism of oncogenesis of HBV-related HCC, even other dis-
eases such as steatosis and fibrosis, leading to identify a
series of new genes involved in these diseases.
In mammals, lethal and disease-related proteins were
found enriched among some proteins that are central to
multiple pathways [38,39], and preferential attachment
to these proteins may be a general hallmark of viral pro-
teins, as has recently been suggested in an analysis of
the literature [40]. An important breakthrough of the
further experimental study is the identification of novel
signaling components and pathways that can be targeted
to develop new therapeutics.
Conclusions
Among the infectious diseases affecting humans, HBV is
one of the most common diseases in the world, particu-
larly in developing countries. More than 350 million
people worldwide are known to be chronic carriers of
HBV, and each year 15 million people die of hepatitis.
HCC is one of the most common fatal cancers world-
wide, and the incidence of HCC in many countries is
increasing in parallel to an increase in chronic HBV
infection. Because the role of HBV infection and the
pathogenic mechanisms of the cancer-causing variant
are not entirely clear, there is still a lack of effective
treatment of HCC. For an in-depth review and under-
standing of these interactions, to enhance insight into
HBV replication and pathogenesis on a cellular level, we
catalogued all published interactions between HBV and
human proteins, particularly human proteins associated
with HCC. We have provided a general overview of the
landscape of human proteins that interact with HBV.
Additional material
Additional file 1: Additional Tables. Table S1. Total interactions
between HBV and human proteins catalogued from related literature.
The meaning of each is as follows: Pubmed_ID: PubMed article ID.
HBV_gene_mention: HBV gene name appeared in the sentence.
HBV_gene: the HBV gene after standardization. verb_mention: the
meaning of the verb or verb noun such as heavier appeared in the
sentence. verb: the verb after standardization. human_gene_mention:
human gene names appeared in the sentence.
human_official_gene_symbol: the human gene after standardization.
human_gene_entrez_ID: standardization of the ID of the human gene.
human_official_gene_description: standardization of the description of
the human gene. sentence: the key sentence. PubMed_link: PubMed
abstract link. Additional file 1, Table S2. Listing and Distribution of
Keywords Associated with the HBV Human Protein Interaction Database.
Statistical analysis of interaction verb and calculation of the proportion of
each verb. Additional file 1, Table S3. Listing of human proteins
interacting with more than one viral protein. Additional file 1, Table S4.
Listing of HHBV-HHBV protein- protein interactions. Interacting human
proteins are referenced with their cognate NCBI gene name (columns 1
and 2). These physical and direct binary protein-protein interactions were
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Page 8 of 10retrieved from the BIND, BioGRID, DIP, GeneRIF, HPRD, IntAct, MINT, and
Reactome databases. Interaction type (6 = KEGG database,7 = text
mining,8 = homology). Additional file 1, Table S5. Hepatocellular
carcinoma-associated proteins (HHCC) catalogued from related literature.
Additional file 1, Table S6. Listing of HHBV-H HCC.H HBV: HBV-interacting
proteins. HHCC: liver cancer-related genes. HHBV-H HCC: overlap. Additional
file 1, Table S7A. Distribution of cellular component Gene Ontology
terms associated with HBV-human protein interactions. Additional file 1,
Table S7B. Distribution of biological process Gene Ontology terms
associated with HBV-human protein interactions Additional file 1, Table
S7C. Distribution of molecular function Gene Ontology terms associated
with HBV-human protein interactions Additional file 1, Table S8.
Functional analysis of the HHBV distribution and enrichment in cellular
pathways using KEGG annotations.
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